Side-by-side comparison of AI visibility scores, market position, and capabilities
Simple PCR-based cancer diagnostics running on standard lab equipment to democratize complex disease detection; $7M raised May 2025 from YC S22 competing with Grail and Exact Sciences for accessible liquid biopsy.
Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.
UK private chef marketplace with 900+ chefs and $6.7M annualized revenue; 45-65% word-of-mouth growth backed by YC and Goodwater Capital expanding to US in 2025.
yhangry is a London-based marketplace connecting customers with 900+ private chefs for in-home dining experiences — enabling individuals, couples, and groups to book a professional chef who shops for ingredients, cooks a multi-course meal in the customer's kitchen, and handles cleanup, for occasions ranging from date nights to dinner parties and corporate events. Founded in 2022 and backed by Y Combinator, Goodwater Capital, and prominent angels with $3.5 million raised, yhangry achieved $6.7 million in annualized revenue in 2024 with 5,300+ bookings and prepares for US expansion in 2025.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.